<DOC>
	<DOCNO>NCT01969058</DOCNO>
	<brief_summary>This phase II study do HIV-infected subject antiretroviral therapy evaluate effect isotretinoin ( drug approve use treatment severe acne ) immune system . Your immune system help body fight infection . When immune system work well , may great risk disease common age , like heart disease , weak bone , kidney disease .</brief_summary>
	<brief_title>Effect Isotretinoin Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery</brief_title>
	<detailed_description />
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>HIV1 infection , document licensed rapid HIV test HIV enzyme chemiluminescence immunoassay ( E/CIA ) test kit time prior study entry confirm licensed Western blot second antibody test method initial rapid HIV and/or E/CIA , HIV1 antigen , plasma HIV1 RNA viral load . NOTE : The term `` license '' refers US FDAapproved kit , require IND study . CDC ( Centers Disease Control Prevention ) guideline mandate confirmation initial test result must use test different one use initial assessment . A reactive initial rapid test confirm either another type rapid assay E/CIA base different antigen preparation and/or different test principle ( eg , indirect versus competitive ) , Western blot plasma HIV1 RNA viral load . Receiving ART therapy least 12 month prior study entry . No plan change ART regimen 6 month study entry . HIV1 RNA low limit detection use FDAapproved assay obtain within 30 day prior study entry laboratory CLIA certification equivalent ( eg , &lt; 50 copies/mL Roche Amplicor HIV1 Monitor assay , &lt; 75 copies/mL Versant HIV1 RNA assay branch DNA , &lt; 40 copies/mL Abbott m2000sp/m2000rt realtime PCR test , &lt; 20 copies/mL COBAS AmpliPrep/TAQMAN HIV1 assay ) . All measurement HIV1 RNA within 12 month prior study entry must limit detection follow exception : NOTE A : 1 viral blip ( &lt; 200 copies/mL ) permit preceded follow viral load limit detection . NOTE B : The virologic assay must lower limit detection ≤ 75 copies/mL . CD4+ cell count &lt; 350 cells/mm3 obtain screen within 30 day prior entry laboratory CLIA ( Clinical Laboratory Improvement Amendments ) certification equivalent . The following laboratory value obtain within 30 day prior entry laboratory CLIA certification equivalent : 1 . Hemoglobin A1c ( HgbA1c ) level ≤ 6.5 % 2 . Hemoglobin ≥ 9.0 g/dL 3 . Platelet count ≥ 50,000/mm3 4 . Creatinine ≤1.5 mg/dl 5 . CrCl ≥ 60 mL/min , calculate CockcroftGault method 6 . Aspartate aminotransferase ( AST ) ( SGOT ) ≤1.5x upper limit normal ( ULN ) 7 . Alanine aminotransferase ( ALT ) ( SGPT ) ≤1.5x ULN 8 . Serum lipase ≤1.5x ULN 9 . Fasting triglyceride level ≤200 mg/dL 10 . Fasting glucose &lt; 126mg/dL Karnofsky performance score &gt; /=70 within 30 day prior entry . Men postmenopausal female age ≥ 18 year ≤ 80 year entry . Note : Postmenopausal define either : 1 . Appropriate medical documentation ( see note ) prior complete bilateral oophorectomy ( i.e. , surgical removal ovary , result `` surgical menopause '' occur age procedure perform ) , OR 2 . Permanent cessation ( 12 consecutive month amenorrhea ) previously occur menses result ovarian failure documentation hormonal deficiency certify healthcare provider ( i.e. , `` spontaneous menopause '' ) . Hormonal deficiency properly document ( see note ) case suspect spontaneous menopause follow : 1 . If age &gt; 54 year absence normal menses : Serum FSH ( Follicle Stimulating Hormone ) level elevate within postmenopausal range base laboratory reference range hormonal assay perform . 2 . If age ≤ 54 year absence normal menses : Negative serum urine HCG concurrently elevate serum FSH ( follicle stimulate hormone ) level postmenopausal range , depress estradiol ( E2 ) level postmenopausal range , absent serum progesterone level , base laboratory reference range hormonal assay perform . NOTE : `` Appropriate documentation '' , `` properly document '' mean write documentation oral communication clinician clinician 's staff document source document operative report , discharge summary , No active hepatitis B C infection . NOTE : For subject documentation prior infection , active hepatitis infection , evidence clearance must great 1 year . Ability willingness subject provide inform consent . Willingness adhere iPLEDGE program requirement . Indication willingness participate substudy A5330s . NOTE : In event 12 few subject enrol A5330s time enrollment main study reach 50 % accrual target , A5330s enrollment require . Preexisting diagnosis diabetes . Currently receive treatment fibrate , nicotinic acid , tetracycline , fish oil &gt; 1g/d , methotrexate . Known active healing fracture severe bone disorder . NOTE : include heal fracture history old fracture . Receipt follow medication within 30 day prior entry : systemic steroid ( include intraarticular steroid ; inhale nasal steroid therapy permit ) , interleukins , systemic interferon ( include intraarticular steroid injection ; local injection interferon alpha treatment human papilloma virus permit ) , systemic chemotherapy . Known allergy/sensitivity hypersensitivity vitamin A , retinoids , derivative . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . Acute serious illness require systemic treatment and/or hospitalization within 60 day prior entry . Weight &lt; 40 kg &gt; 150 kg . History major depression suicide attempt require hospitalization , psychotic episode require medication hospitalization . History inflammatory bowel disease Crohn 's disease , Ulcerative colitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>